1,4-dibenzylpiperidine-4-carbonitrile | 173086-95-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1,4-dibenzylpiperidine-4-carbonitrile
• 英文别名: 1,4-Dibenzyl-4-cyanopiperidine
• CAS: 173086-95-8
• 化学式: C₂₀H₂₂N₂
• 分子量: 290.408
• InChiKey: GTCHJPFUTLXTMN-UHFFFAOYSA-N

物化性质

• 沸点：
  437.7±38.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,4-dibenzylpiperidine-4-carbonitrile 在 氨 、 氢气 作用下， 以 甲醇 为溶剂， 以61%的产率得到4-(aminomethyl)-1-benzyl-N-phenylpiperidin-4-amine
  参考文献：
  名称：

  Nonpeptide Small Molecule Agonist and Antagonist Original Leads for Neuropeptide FF1 and FF2 Receptors

  摘要：

  Neuropeptide FF1 and FF2 receptors (NPFF1-R and NPFF2-R), and their endogenous ligand NPFF, are one of only several systems responsible for mediating opioid-induced hyperalgesia, tolerance, and dependence. Currently, no small molecules displaying good affinity or selectivity for either subtype have been reported, to decipher the role of NPFF2-R as it relates to opioid-mediated analgesia, for further exploration of NPFF1-R, or for medication development for either subtype. We report the first nonpeptide small molecule scaffold for NPFF1,2-R, the guanidino-piperidines, and SAR studies resulting in the discovery of a NPFF1 agonist (7b, K-i = 487 +/- 117 nM), a NPFF1 antagonist (46, K-i = 81 +/- 17 nM), and a NPFF2 partial antagonist (53a, K-i = 30 +/- 5 nM), which serve as leads for the development of pharmacological probes and potential therapeutic agents. Testing of 46 alone was without effect in the mouse 48 degrees C warm-water tail-withdrawal test, but pretreatment with 46 prevented NPFF-induced hyperalgesia.

  DOI：

  10.1021/jm500989n
• 作为产物：
  描述：

  溴甲苯 、 1-苄基-4-氰基哌啶 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正庚烷 、 乙基苯 为溶剂， 反应 2.5h， 以89%的产率得到1,4-dibenzylpiperidine-4-carbonitrile
  参考文献：
  名称：

  Nonpeptide Small Molecule Agonist and Antagonist Original Leads for Neuropeptide FF1 and FF2 Receptors

  摘要：

  Neuropeptide FF1 and FF2 receptors (NPFF1-R and NPFF2-R), and their endogenous ligand NPFF, are one of only several systems responsible for mediating opioid-induced hyperalgesia, tolerance, and dependence. Currently, no small molecules displaying good affinity or selectivity for either subtype have been reported, to decipher the role of NPFF2-R as it relates to opioid-mediated analgesia, for further exploration of NPFF1-R, or for medication development for either subtype. We report the first nonpeptide small molecule scaffold for NPFF1,2-R, the guanidino-piperidines, and SAR studies resulting in the discovery of a NPFF1 agonist (7b, K-i = 487 +/- 117 nM), a NPFF1 antagonist (46, K-i = 81 +/- 17 nM), and a NPFF2 partial antagonist (53a, K-i = 30 +/- 5 nM), which serve as leads for the development of pharmacological probes and potential therapeutic agents. Testing of 46 alone was without effect in the mouse 48 degrees C warm-water tail-withdrawal test, but pretreatment with 46 prevented NPFF-induced hyperalgesia.

  DOI：

  10.1021/jm500989n

文献信息

• [EN] SUBSTITUTED HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME<br/>[FR] COMPOSES HETEROCYCLIQUES SUBSTITUES, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SANOFI

  公开号：WO1996023787A1

  公开（公告）日：1996-08-08

  (EN) Compounds of formula (I), wherein A is a bivalent radical selected from: A1)-O-CO-, A2)-CH2-O-CO-, A3)-O-CH2-CO-, A4)-O-CH2-CH2-, A5-N(R1)-CO-, A6)-N(R1)-CO-CO-, A7)-N(R1)-CH2-CH2-, A8)-O-CH2-, where R1 is hydrogen or C1-4alkyl, and Am is a heterocyclic nitrogen ring, are provided for use as neurokinin receptor antagonists.(FR) L'invention a pour objet des composés de formula (I) dans laquelle A représente un radical bivalent choisi parmi: A1)-O-CO-, A2)-CH2-O-CO-, A3)-O-CH2-CO-, A4)-O-CH2-CH2-, A5-N(R1)-CO-, A6)-N(R1)-CO-CO-, A7)-N(R1)-CH2-CH2-, A8)-O-CH2-, dans lesquels R1 représente un hydrogène ou un (C1-C4)alkyle, Am représente un hétérocyclique azoté. Application: antagonistes des récepteurs des neurokinines.

  化合物的式子为（I），其中A是双价基团，选择自：A1）-O-CO-，A2）-CH2-O-CO-，A3）-O-CH2-CO-，A4）-O-CH2-CH2-，A5-N（R1）-CO-，A6）-N（R1）-CO-CO-，A7）-N（R1）-CH2-CH2-，A8）-O-CH2-，其中R1表示氢或C1-4烷基，而Am是一个杂环氮环，用作神经激肽受体拮抗剂。
• Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them
  申请人：——

  公开号：US20040220223A1

  公开（公告）日：2004-11-04

  Compounds of formula (I), a method for obtaining them and pharmaceutical compositions containing them are described. The compounds are useful as human NK 3 receptor antagonists.

  本文描述了化学式（I）的化合物，获得它们的方法以及含有它们的药物组合物。这些化合物可用作人类NK3受体拮抗剂。
• Substituted heterocyclic compounds and pharmaceutical compositions in
  申请人：Sanofi

  公开号：US05641777A1

  公开（公告）日：1997-06-24

  The invention relates to neurokinin receptor antagonist compounds of the formula ##STR1## in which: A is a divalent radical selected from: A.sub.1) --O--CO-- A.sub.2) --CH.sub.2 --O--CO-- A.sub.3) --O--CH.sub.2 --CO-- A.sub.4) --O--CH.sub.2 --CH.sub.2 -- A.sub.5) --N(R.sub.1)--CO-- A.sub.6) --N(R.sub.1)--CO--CO-- A.sub.7) --N(R.sub.1)--CH.sub.2 --CH.sub.2 -- A.sub.8) --O--CH.sub.2 -- in which: R.sub.1 is a hydrogen or a (C.sub.1 -C.sub.4)-alkyl; and Am is a nitrogen-containing heterocycle APPLICATION: Neurokinin receptor antagonists.

  本发明涉及公式为##STR1##的神经激肽受体拮抗剂化合物，其中：A是二价基团，选自：A.sub.1) --O--CO-- A.sub.2) --CH.sub.2 --O--CO-- A.sub.3) --O--CH.sub.2 --CO-- A.sub.4) --O--CH.sub.2 --CH.sub.2 -- A.sub.5) --N(R.sub.1)--CO-- A.sub.6) --N(R.sub.1)--CO--CO-- A.sub.7) --N(R.sub.1)--CH.sub.2 --CH.sub.2 -- A.sub.8) --O--CH.sub.2 -- 其中：R.sub.1是氢或（C.sub.1-C.sub.4）-烷基；Am是含氮杂环。应用：神经激肽受体拮抗剂。
• Substituted arylaliphatic compounds, method of preparing them and
  申请人：Sanofi

  公开号：US05726313A1

  公开（公告）日：1998-03-10

  Compound of Formula (I), wherein W.sub.1 is an oxygen atom; an --NR-- group wherein R is hydrogen, C.sub.1 -C.sub.7 alkyl or benzyl; and B is for example a substituted piperidine or quinuclidine. The disclosed compounds are useful as neurokinin receptor antagonists.

  化合物为式（I），其中W.sub.1是一个氧原子；一个--NR--基团，其中R为氢，C.sub.1-C.sub.7烷基或苄基；B例如为取代的哌啶或喹诺啉。所披露的化合物可用作神经激肽受体拮抗剂。
• Substituted heterocyclic compounds, method of preparing them and
  申请人：Sanofi

  公开号：US06011154A1

  公开（公告）日：2000-01-04

  The invention relates to compounds of the formula ##STR1## in which: A is a divalent radical selected from: A.sub.1) --O--CO-- A.sub.2) --CH.sub.2 --O--CO-- A.sub.3) --O--CH.sub.2 --CO-- A.sub.4) --O--CH.sub.2 --CH.sub.2 -- A.sub.5) --N(R.sub.1)--CO-- A.sub.6) --N(R.sub.1)--CO--CO-- A.sub.7) --N(R.sub.1)--CH.sub.2 --CH.sub.2 -- A.sub.8) --O--CH.sub.2 -- in which: R.sub.1 is a hydrogen or a (C.sub.1 -C.sub.4)-alkyl; and Am is a nitrogen-containing heterocycle.

  该发明涉及以下式子的化合物：##STR1## 其中：A是从以下二价基团中选择的：A.sub.1) --O--CO-- A.sub.2) --CH.sub.2 --O--CO-- A.sub.3) --O--CH.sub.2 --CO-- A.sub.4) --O--CH.sub.2 --CH.sub.2 -- A.sub.5) --N(R.sub.1)--CO-- A.sub.6) --N(R.sub.1)--CO--CO-- A.sub.7) --N(R.sub.1)--CH.sub.2 --CH.sub.2 -- A.sub.8) --O--CH.sub.2 -- 其中：R.sub.1是氢或(C.sub.1-C.sub.4)-烷基；Am是含氮杂环。